866 Halei Road
Pudong New Area
About Harbour BiomedHarbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer with a focus on immuno-oncology. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery. The company is building its proprietary pipeline internally, through collaborations with co-development partners, as well as through selective preclinical and clinical stage asset acquisitions. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary.
Founder: Frank Grosveld and Roger Craig
CEO: Jingsong Wang
CSO: Liang Schweizer
CFO: Jeff He
Please click here for Harbour Biomed job opportunities.
Please click here for clinical trial information.
64 articles with Harbour Biomed
Harbour BioMed Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003
Harbour BioMed announced that the China National Medical Products Administration has approved its Investigational New Drug applications for HBM4003, a next-generation, fully human anti-CTLA-4 monoclonal heavy chain only antibody in combination with PD-1 antibody in patients with advanced hepatocellular carcinoma and other solid tumors, as well as advanced neuroendocrine tumor/neuroendocrine carcinoma and other solid tumors.
Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003
Harbour BioMed announced positive results from its phase I dose escalation clinical trial of HBM4003 in solid tumors in Australia.
Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China
Harbour BioMed announced that the Center for Drug Evaluation of China National Medical Products Administration has approved the Investigational New Drug application to initiate phase II trial of Anti-FcRn Batoclimab in patients with Chronic Inflammatory Demyelinating Polyneuropathy.
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, reported its interim results for the six months ended June 30, 2021, and provided key business updates.
Harbour BioMed announced that the abstract detailing clinical data from its Australian phase I study of next-generation anti-CTLA-4 antibody in patients with advanced solid tumors will be presented as an e-poster at the 2021 European Society for Medical Oncology Congress, which is expected to be held 16-21 September 2021.
Harbour BioMed announced the appointment of Dr. Yingying Chen as Chief Financial Officer. Dr. Chen will be responsible for leading the overall management of Finance & Investor Relations and overseeing all aspects of financial operations.
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC
Harbour BioMed announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study.
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment
Harbour BioMed announced it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer treatment.
The research collaboration will see the development of bispecific antibodies and CAR-T cell products.
Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody
Harbour BioMed announced the dosing of the first patient in its part 2 of phase I clinical study of its next-generation anti-CTLA-4 antibody, where Australian patients with metastatic or advanced melanoma, hepatocellular carcinoma and renal cell carcinoma and other type of tumors will be enrolled.
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting
Harbour BioMed, a global clinical-stage biopharmaceutical company, presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting.
Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China
Harbour BioMed announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors.
Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in the Phase III clinical trial of its new global investigational tumor necrosis factor (TNF) receptor-1 fragment-based drug Tanfanercept (HBM9036) for adult patients with moderate-to-severe dry eye disease (DED) in China.
Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis
Harbour BioMed, announced that China Center for Drug Evaluation has granted Breakthrough Therapy designation to Batoclimab, a fully human anti-FcRn monoclonal antibody, for the treatment of adult patients with Myasthenia Gravis.
Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie.
Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society
The proof-of-concept study demonstrated efficacy, safety, and tolerability of Tanfanercept for the treatment of moderate-to-severe dry eye disease (DED) in China
Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors
Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND) applications by the China National Medical Products Administration (NMPA) of its next-generation fully human anti-CTLA-4 antibody (HBM4003).
Harbour BioMed and Hualan Genetic Announced Collaboration to Develop Multiple Innovative Antibody Programs
Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company today announced a strategic partnership agreement with Hualan Genetic Engineering Co., Ltd (Hualan Genetic) to develop HBM's three proprietary innovative monoclonal and bispecific antibodies.
Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020
Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, presented its newly discovered novel anti-human CCR8 mAbs at the 16th PEGS Boston Summit.
Harbour BioMed Will Present Its New Platform HBICE (Heavy chain only antibody (HCAb) Based Immune Cell Engager) at 16th PEGS Boston Summit
Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, today announced that it presented its newly developed HBICE TM (HCAb Based Immune Cell Engager) platform and its ability to generate fast and reliable next-generation bispecific antibodies for immunotherapies at the 16th PEGS Boston Summit. The poster will